Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Bioavailability Enhancement: Drug Permeability Enhancement

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Drug Delivery: Miscellaneous Routes

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

4,4'-DMAR <i>in-vivo</i> acute cardiotoxicity: differences between (±)<i>cis</i>-4,4'-DMAR and its coadministration with the (±)<i>trans</i>-4,4'-DMAR isomer.

Frontiers in cardiovascular medicine·2026

Same author

Genotoxic Potential of Metodesnitazene and Etodesnitazene: Insights with and Without S9 Metabolic Activation.

International journal of molecular sciences·2026

Same author

The Synthetic Cannabinoid AKB-48 Induces Cell Death in Murine Cerebellum Through Different Signaling Pathways.

International journal of molecular sciences·2026

Same author

5-HT<sub>2A</sub> receptor agonism by tert-leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence.

British journal of pharmacology·2026

Same author

Sex-related pharmacokinetic and pharmacological responses to 4F-furanylfentanyl.

Frontiers in pharmacology·2026

Same author

In Vitro Cytotoxic and Genotoxic Evaluation of Nitazenes, a Potent Class of New Synthetic Opioids.

Journal of xenobiotics·2025

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Solid lipid nanoparticles as delivery systems for bromocriptine.

Elisabetta Esposito¹, Martina Fantin, Matteo Marti

¹Department of Pharmaceutical Sciences, University of Ferrara, 44100 Ferrara, Italy. ese@unife.it

Pharmaceutical Research

|January 4, 2008

Summary

Nanostructured lipid carriers effectively encapsulate bromocriptine, prolonging its therapeutic effect for Parkinson's disease treatment. This drug delivery system enhances antiparkinsonian activity and stability.

More Related Videos

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Published on: November 17, 2015

Related Experiment Videos

Last Updated: Jul 8, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Published on: November 17, 2015

Area of Science:

Pharmaceutical Sciences
Nanotechnology
Neuroscience

Background:

Bromocriptine is a dopamine agonist used to treat Parkinson's disease.
Current formulations may have limitations in sustained drug delivery.
Innovative drug delivery systems are needed to improve bromocriptine's efficacy and duration of action.

Purpose of the Study:

To develop and characterize novel nanostructured lipid carriers (NLCs) for bromocriptine delivery.
To evaluate the antiparkinsonian activity of bromocriptine-loaded NLCs in an animal model.

Main Methods:

Solid lipid nanoparticles (SLNs) were formulated using various lipidic components, including a tristearin/tricaprin mixture.
Nanoparticle characterization involved electron microscopy and Photon Correlation Spectroscopy.
Antiparkinsonian activity was assessed in 6-hydroxydopamine hemilesioned rats.

Main Results:

Tristearin/tricaprin NLCs exhibited stable particle size for up to 6 months.
High bromocriptine entrapment efficiency was achieved, particularly with the tristearin/tricaprin formulation.
In vitro studies showed prolonged bromocriptine release over 48 hours, with NLCs providing better control.
Bromocriptine-loaded NLCs demonstrated a more rapid onset and prolonged duration of antiparkinsonian effect in rats.

Conclusions:

NLCs represent a promising strategy for enhancing bromocriptine delivery.
Encapsulation in NLCs can prolong the half-life and improve the therapeutic efficacy of bromocriptine.
This formulation approach holds potential for improved Parkinson's disease management.